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JAMA Pediatrics, July 2016, Online First
KEY FINDINGS: State mandates requiring commercial health plans to cover services for children with autism spectrum
disorder increased the number of children diagnosed with the disorder. However, diagnosis rates remain much lower than
community estimates, suggesting that many commercially insured children with ASD remain undiagnosed or are insured
through public plans.

THE QUESTION
Responding to the growing prevalence of autism spectrum
disorder (ASD) among children, and insurer reluctance to
pay for expensive treatments, 44 states now have mandates
requiring commercial plans to cover behavioral services for
children with ASD. These mandates apply to state-regulated
plans but do not apply to large, self-insured employer group
plans, which are federally-regulated. The state mandates
vary in terms of the age ranges they cover and the kinds of
plans to which they apply.
Insurers have opposed the mandates, which they claimed
would dramatically increase the number of children diagnosed
with ASD and drastically increase health spending. ASD is
thought to be underdiagnosed with its treated prevalence –
the number of individuals diagnosed with ASD in the health
care system – far below the Centers for Disease Control and
Prevention’s estimated community prevalence of 15 per
1,000 children. But little is known about the actual effects of
these mandates. David Mandell and colleagues used claims
data from three large national insurers to analyze the effects
of state mandates on the rate at which commercially insured
children are diagnosed with ASD.

THE FINDINGS
Twenty-nine states had ASD insurance mandates during
the study period, 2008-2013. Indiana was the first state to

implement a mandate in 2001, followed by three states in 2008
(Illinois, South Carolina, and Texas), before the start of the
study. During the study period, mandates were implemented
by six states in 2009 (Arizona, Florida, Louisiana, New
Mexico, Pennsylvania, and Wisconsin), four states in 2010
(Colorado, Connecticut, Montana, and New Jersey), eight
states in 2011 (Arkansas, Kentucky, Massachusetts, Maine,
Missouri, New Hampshire, Nevada, and Vermont), and
seven states in 2012 (California, Delaware, Michigan, New
York, Rhode Island, Virginia, and West Virginia). All state
mandates applied to fully insured firms with more than 50
employees; 22 of the 29 state mandates also applied to fully
insured firms with 50 or fewer employees. By the end of
the study period, 18 of the 29 mandates covered individuals
from birth through 18 years or older.
Of the more than one million children in the claims data
sample, the authors identified 154,089 children diagnosed
with ASD. Controlling for time trends and demographic
factors, the study found that implementation of a mandate
was associated with an increase of 12.7% in the treated
prevalence of eligible children with ASD over the study
period, with the effects building over time — 10.4% in the
first year of the mandate, 17.1% in the second year, and
18.0% in the third and later years. The adjusted prevalence
rate was 1.8 per 1,000 children in states with ASD insurance
mandates and 1.6 per 1,000 children in states without such
a mandate.
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These findings indicate that the mandates are having their
intended effects, and that those effects build over time. But
even three years or more after implementation, the treated
prevalence of ASD was much lower than community
prevalence estimates. This finding may allay concerns that
mandates will substantially increase insurance costs, but
it suggests that many commercially insured children with
ASD remain undiagnosed or are being treated only through
publicly funded systems.
It is clear that the mandates have not had the full effect
that advocates desired. The authors note that the shortfall
might be due to vague and difficult regulatory processes that
providers must follow, low reimbursements for assessment
and treatment, and a shortage of qualified clinicians to meet
the growing demand for ASD-related care. The results
suggest the need for additional strategies to enforce the
mandates and address regulatory and health system-related
barriers that inhibit the timely and appropriate identification
of children with ASD.

THE STUDY
The authors used combined claims data (assembled by
the Health Care Cost Institute) from three large, national
health insurance companies: United Healthcare, Aetna and
Humana. They identified 154,089 children (birth through 21
years) diagnosed with ASD during the five-year study period
from January 2008 through December 2012. To identify
whether a child resided in a state with an implemented
ASD mandate law, they compiled detailed information
from Autism Speaks about state mandates, and verified the
information by reviewing the original mandate laws.
They compared the treated prevalence of ASD within states
before and after mandate implementation, and between
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groups of children who would and would not be affected by
the laws based on the source of their health insurance and their
age. They compared four groups of children: those in states
with active ASD insurance mandates, who were subject to
the mandate; those in states with an active mandate who were
not subject to the mandate; those in states without a mandate
who would have been subject to the mandate if one were
active; and those in states without a mandate who would not
have been subject to the mandate if one were active. The use
of comparison groups of children in states without mandates
accounted for secular trends in treated prevalence unrelated
to state ASD mandate laws. In addition, the authors looked at
whether the effect of the mandates changed over time, based on
how many years a law had been in place.
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